1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Tibet Pharmaceuticals, Inc.

Tibet Pharmaceuticals, Inc.

TBET
Tibet Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
1,485.00Market Cap

Total Valuation

Tibet Pharmaceuticals, Inc. carries a market capitalization of 1,485.00, placing it among publicly traded companies globally. Its enterprise value stands at -10.27M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1,485.00
Enterprise Value-10.27M

Share Statistics

Tibet Pharmaceuticals, Inc. currently has 14.85M shares outstanding.

Shares Outstanding14.85M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Tibet Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 1.45. The price-to-sales ratio is 0.46, and the price-to-book ratio stands at 0.92.

PE Ratio1.45
PS Ratio0.46
PB Ratio0.92
P/TBV Ratio0.34
P/FCF Ratio2.60
P/OCF Ratio2.60

Enterprise Valuation

The EV/Sales ratio of 1.32 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 3.42 provides insight into valuation relative to core operating earnings.

EV / Sales1.32
EV / EBITDA3.18
EV / EBIT3.42
EV / FCFN/A

Financial Position

Tibet Pharmaceuticals, Inc. maintains a current ratio of 14.48, meaning it holds 14.5x the short-term assets needed to cover near-term liabilities.

Current Ratio14.48
Quick Ratio13.90
Debt / EquityN/A
Debt / EBITDAN/A
Interest Coverage228.91

Financial Efficiency

Tibet Pharmaceuticals, Inc. posts a return on equity of 88.18 and a return on invested capital of 30.24.

Return on Equity (ROE)88.18
Return on Assets (ROA)27.98
Return on Invested Capital (ROIC)30.24
Return on Capital Employed (ROCE)77.14
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover11.10

Stock Price Statistics

Tibet Pharmaceuticals, Inc.'s stock has gained approximately 0.000003% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Beta (5Y)N/A
52-Week Price Change0.000003%
50-Day Moving Average0.00
200-Day Moving Average0.00
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Tibet Pharmaceuticals, Inc. generated 34.05M in revenue and converted that into 10.82M in net income, yielding earnings per share of 0.75. EBITDA reached 11.75M, while operating income came in at 10.80M.

Revenue34.05M
Gross Profit14.17M
Operating Income10.80M
Pretax Income5.18M
Net Income10.82M
EBITDA11.75M
EBIT10.80M
Earnings Per Share (EPS)0.75

Balance Sheet

Total book value stands at 17.07M, with working capital of 40.72M providing operational flexibility.

Cash & Cash Equivalents25.96M
Total DebtN/A
Net Debt-25.96M
Equity (Book Value)17.07M
Book Value Per Share1.19
Working Capital40.72M

Cash Flow

Tibet Pharmaceuticals, Inc. produced 6.03M in operating cash flow over the past twelve months. After subtracting -8,271.00 in capital expenditures, free cash flow totaled 6.02M - equivalent to 0.42 per share.

Operating Cash Flow6.03M
Capital Expenditures-8,271.00
Free Cash Flow6.02M
FCF Per Share0.42

Margins

Tibet Pharmaceuticals, Inc. operates with a gross margin of 41.60, reflecting its pricing power and cost economics. The operating margin of 31.70 and net profit margin of 31.79 provide insight into operational efficiency.

Gross Margin41.60
Operating Margin31.70
Pretax Margin15.21
Profit Margin31.79
EBITDA Margin34.50

Dividends & Yields

The company's payout ratio of 0.17 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.00
Dividend YieldN/A
Payout Ratio0.17
Shareholder Yield-68.12
FCF Yield38.51

Scores

Tibet Pharmaceuticals, Inc. posts an Altman Z-Score of 5.98, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.98